Ontology type: schema:ScholarlyArticle Open Access: True
2021-09-06
AUTHORSMarwa M. Abu‑Serie, Marwa Eltarahony
ABSTRACTBackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS–Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS–CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50 < 15 nM), against human breast, lung and liver cancer cells, by >10-fold, compared to DS–Cu, CuO NPs and Cu. Importantly, DS–CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS–Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-κB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS–Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract More... »
PAGES25
http://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5
DOIhttp://dx.doi.org/10.1186/s12645-021-00097-5
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1140919775
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Pharmacology and Pharmaceutical Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt",
"id": "http://www.grid.ac/institutes/grid.420020.4",
"name": [
"Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt"
],
"type": "Organization"
},
"familyName": "Abu\u2011Serie",
"givenName": "Marwa M.",
"id": "sg:person.01232563730.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232563730.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt",
"id": "http://www.grid.ac/institutes/grid.420020.4",
"name": [
"Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt"
],
"type": "Organization"
},
"familyName": "Eltarahony",
"givenName": "Marwa",
"id": "sg:person.016243533706.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016243533706.44"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/1477-3155-12-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031265962",
"https://doi.org/10.1186/1477-3155-12-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41598-021-87363-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1136991621",
"https://doi.org/10.1038/s41598-021-87363-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10529-017-2463-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1092556456",
"https://doi.org/10.1007/s10529-017-2463-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2402417",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044065576",
"https://doi.org/10.1038/sj.leu.2402417"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11064-015-1688-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019091227",
"https://doi.org/10.1007/s11064-015-1688-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.2012.442",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025902917",
"https://doi.org/10.1038/bjc.2012.442"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-09-06",
"datePublishedReg": "2021-09-06",
"description": "BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS\u2013Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS\u2013CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50\u2009<\u200915\u00a0nM), against human breast, lung and liver cancer cells, by\u2009>10-fold, compared to DS\u2013Cu, CuO NPs and Cu. Importantly, DS\u2013CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS\u2013Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-\u03baB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS\u2013Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract",
"genre": "article",
"id": "sg:pub.10.1186/s12645-021-00097-5",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1042272",
"issn": [
"1868-6958",
"1868-6966"
],
"name": "Cancer Nanotechnology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "12"
}
],
"keywords": [
"selective anticancer activity",
"anticancer activity",
"anti-metastatic potential",
"matrix metallopeptidase 9",
"anticancer efficacy",
"clinical application",
"half-maximum inhibitory concentration",
"broad anticancer activity",
"low half-maximum inhibitory concentration",
"liver cancer cells",
"synergistic anticancer effect",
"metallopeptidase 9",
"NF-\u03baB",
"therapeutic index",
"p53 expression",
"animal models",
"anticancer effects",
"cellular uptake",
"human breast",
"cancer cells",
"inhibitory concentration",
"novel nanoformulation",
"further investigation",
"higher cellular uptake",
"efficacy",
"future studies",
"promising nanomedicine",
"novel nanocomplex",
"lung",
"activity",
"breast",
"copper oxide nanoparticles",
"uptake",
"disulfiram",
"serum",
"ResultsThe",
"poor solubility",
"apoptosis",
"novel nanocombination",
"ConclusionAll",
"study",
"oxide nanoparticles",
"CuO NPs",
"cells",
"expression",
"nanoformulations",
"findings",
"nanocomplexes",
"presence of copper",
"index",
"DS",
"high stability",
"effect",
"presence",
"concentration",
"DS-Cu",
"nanomedicine",
"nanoparticles",
"species content",
"complexes",
"potential",
"investigation",
"NPs",
"preliminary step",
"stability",
"solubility",
"nanocharacterization",
"copper",
"Cu",
"content",
"model",
"applications",
"design",
"step",
"defenders"
],
"name": "Novel nanoformulation of disulfiram with bacterially synthesized copper oxide nanoparticles for augmenting anticancer activity: an in vitro study",
"pagination": "25",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1140919775"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12645-021-00097-5"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12645-021-00097-5",
"https://app.dimensions.ai/details/publication/pub.1140919775"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:39",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_919.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12645-021-00097-5"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'
This table displays all metadata directly associated to this object as RDF triples.
166 TRIPLES
22 PREDICATES
106 URIs
92 LITERALS
6 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s12645-021-00097-5 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1115 |
3 | ″ | schema:author | N57190132f6bd417d9043335454cf3432 |
4 | ″ | schema:citation | sg:pub.10.1007/s10529-017-2463-6 |
5 | ″ | ″ | sg:pub.10.1007/s11064-015-1688-9 |
6 | ″ | ″ | sg:pub.10.1038/bjc.2012.442 |
7 | ″ | ″ | sg:pub.10.1038/s41598-021-87363-z |
8 | ″ | ″ | sg:pub.10.1038/sj.leu.2402417 |
9 | ″ | ″ | sg:pub.10.1186/1477-3155-12-5 |
10 | ″ | schema:datePublished | 2021-09-06 |
11 | ″ | schema:datePublishedReg | 2021-09-06 |
12 | ″ | schema:description | BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS–Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS–CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50 < 15 nM), against human breast, lung and liver cancer cells, by >10-fold, compared to DS–Cu, CuO NPs and Cu. Importantly, DS–CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS–Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-κB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS–Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract |
13 | ″ | schema:genre | article |
14 | ″ | schema:inLanguage | en |
15 | ″ | schema:isAccessibleForFree | true |
16 | ″ | schema:isPartOf | N556300cd3eb5438fb19d64cec2025ec9 |
17 | ″ | ″ | Ncb635fb6134141709e8d5c52970e7874 |
18 | ″ | ″ | sg:journal.1042272 |
19 | ″ | schema:keywords | ConclusionAll |
20 | ″ | ″ | Cu |
21 | ″ | ″ | CuO NPs |
22 | ″ | ″ | DS |
23 | ″ | ″ | DS-Cu |
24 | ″ | ″ | NF-κB |
25 | ″ | ″ | NPs |
26 | ″ | ″ | ResultsThe |
27 | ″ | ″ | activity |
28 | ″ | ″ | animal models |
29 | ″ | ″ | anti-metastatic potential |
30 | ″ | ″ | anticancer activity |
31 | ″ | ″ | anticancer effects |
32 | ″ | ″ | anticancer efficacy |
33 | ″ | ″ | apoptosis |
34 | ″ | ″ | applications |
35 | ″ | ″ | breast |
36 | ″ | ″ | broad anticancer activity |
37 | ″ | ″ | cancer cells |
38 | ″ | ″ | cells |
39 | ″ | ″ | cellular uptake |
40 | ″ | ″ | clinical application |
41 | ″ | ″ | complexes |
42 | ″ | ″ | concentration |
43 | ″ | ″ | content |
44 | ″ | ″ | copper |
45 | ″ | ″ | copper oxide nanoparticles |
46 | ″ | ″ | defenders |
47 | ″ | ″ | design |
48 | ″ | ″ | disulfiram |
49 | ″ | ″ | effect |
50 | ″ | ″ | efficacy |
51 | ″ | ″ | expression |
52 | ″ | ″ | findings |
53 | ″ | ″ | further investigation |
54 | ″ | ″ | future studies |
55 | ″ | ″ | half-maximum inhibitory concentration |
56 | ″ | ″ | high stability |
57 | ″ | ″ | higher cellular uptake |
58 | ″ | ″ | human breast |
59 | ″ | ″ | index |
60 | ″ | ″ | inhibitory concentration |
61 | ″ | ″ | investigation |
62 | ″ | ″ | liver cancer cells |
63 | ″ | ″ | low half-maximum inhibitory concentration |
64 | ″ | ″ | lung |
65 | ″ | ″ | matrix metallopeptidase 9 |
66 | ″ | ″ | metallopeptidase 9 |
67 | ″ | ″ | model |
68 | ″ | ″ | nanocharacterization |
69 | ″ | ″ | nanocomplexes |
70 | ″ | ″ | nanoformulations |
71 | ″ | ″ | nanomedicine |
72 | ″ | ″ | nanoparticles |
73 | ″ | ″ | novel nanocombination |
74 | ″ | ″ | novel nanocomplex |
75 | ″ | ″ | novel nanoformulation |
76 | ″ | ″ | oxide nanoparticles |
77 | ″ | ″ | p53 expression |
78 | ″ | ″ | poor solubility |
79 | ″ | ″ | potential |
80 | ″ | ″ | preliminary step |
81 | ″ | ″ | presence |
82 | ″ | ″ | presence of copper |
83 | ″ | ″ | promising nanomedicine |
84 | ″ | ″ | selective anticancer activity |
85 | ″ | ″ | serum |
86 | ″ | ″ | solubility |
87 | ″ | ″ | species content |
88 | ″ | ″ | stability |
89 | ″ | ″ | step |
90 | ″ | ″ | study |
91 | ″ | ″ | synergistic anticancer effect |
92 | ″ | ″ | therapeutic index |
93 | ″ | ″ | uptake |
94 | ″ | schema:name | Novel nanoformulation of disulfiram with bacterially synthesized copper oxide nanoparticles for augmenting anticancer activity: an in vitro study |
95 | ″ | schema:pagination | 25 |
96 | ″ | schema:productId | N79d3b702eb0c4671847f86b760c93d0b |
97 | ″ | ″ | Nfadeef725c1a4cb787b9eb0b2a9e9dea |
98 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1140919775 |
99 | ″ | ″ | https://doi.org/10.1186/s12645-021-00097-5 |
100 | ″ | schema:sdDatePublished | 2022-05-20T07:39 |
101 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
102 | ″ | schema:sdPublisher | Nffa00bed541d454e92a22823344ca509 |
103 | ″ | schema:url | https://doi.org/10.1186/s12645-021-00097-5 |
104 | ″ | sgo:license | sg:explorer/license/ |
105 | ″ | sgo:sdDataset | articles |
106 | ″ | rdf:type | schema:ScholarlyArticle |
107 | N556300cd3eb5438fb19d64cec2025ec9 | schema:volumeNumber | 12 |
108 | ″ | rdf:type | schema:PublicationVolume |
109 | N57190132f6bd417d9043335454cf3432 | rdf:first | sg:person.01232563730.11 |
110 | ″ | rdf:rest | Na0fccc09150043989396ea8818c085b2 |
111 | N79d3b702eb0c4671847f86b760c93d0b | schema:name | dimensions_id |
112 | ″ | schema:value | pub.1140919775 |
113 | ″ | rdf:type | schema:PropertyValue |
114 | Na0fccc09150043989396ea8818c085b2 | rdf:first | sg:person.016243533706.44 |
115 | ″ | rdf:rest | rdf:nil |
116 | Ncb635fb6134141709e8d5c52970e7874 | schema:issueNumber | 1 |
117 | ″ | rdf:type | schema:PublicationIssue |
118 | Nfadeef725c1a4cb787b9eb0b2a9e9dea | schema:name | doi |
119 | ″ | schema:value | 10.1186/s12645-021-00097-5 |
120 | ″ | rdf:type | schema:PropertyValue |
121 | Nffa00bed541d454e92a22823344ca509 | schema:name | Springer Nature - SN SciGraph project |
122 | ″ | rdf:type | schema:Organization |
123 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
124 | ″ | schema:name | Medical and Health Sciences |
125 | ″ | rdf:type | schema:DefinedTerm |
126 | anzsrc-for:1115 | schema:inDefinedTermSet | anzsrc-for: |
127 | ″ | schema:name | Pharmacology and Pharmaceutical Sciences |
128 | ″ | rdf:type | schema:DefinedTerm |
129 | sg:journal.1042272 | schema:issn | 1868-6958 |
130 | ″ | ″ | 1868-6966 |
131 | ″ | schema:name | Cancer Nanotechnology |
132 | ″ | schema:publisher | Springer Nature |
133 | ″ | rdf:type | schema:Periodical |
134 | sg:person.01232563730.11 | schema:affiliation | grid-institutes:grid.420020.4 |
135 | ″ | schema:familyName | Abu‑Serie |
136 | ″ | schema:givenName | Marwa M. |
137 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232563730.11 |
138 | ″ | rdf:type | schema:Person |
139 | sg:person.016243533706.44 | schema:affiliation | grid-institutes:grid.420020.4 |
140 | ″ | schema:familyName | Eltarahony |
141 | ″ | schema:givenName | Marwa |
142 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016243533706.44 |
143 | ″ | rdf:type | schema:Person |
144 | sg:pub.10.1007/s10529-017-2463-6 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1092556456 |
145 | ″ | ″ | https://doi.org/10.1007/s10529-017-2463-6 |
146 | ″ | rdf:type | schema:CreativeWork |
147 | sg:pub.10.1007/s11064-015-1688-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1019091227 |
148 | ″ | ″ | https://doi.org/10.1007/s11064-015-1688-9 |
149 | ″ | rdf:type | schema:CreativeWork |
150 | sg:pub.10.1038/bjc.2012.442 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1025902917 |
151 | ″ | ″ | https://doi.org/10.1038/bjc.2012.442 |
152 | ″ | rdf:type | schema:CreativeWork |
153 | sg:pub.10.1038/s41598-021-87363-z | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1136991621 |
154 | ″ | ″ | https://doi.org/10.1038/s41598-021-87363-z |
155 | ″ | rdf:type | schema:CreativeWork |
156 | sg:pub.10.1038/sj.leu.2402417 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1044065576 |
157 | ″ | ″ | https://doi.org/10.1038/sj.leu.2402417 |
158 | ″ | rdf:type | schema:CreativeWork |
159 | sg:pub.10.1186/1477-3155-12-5 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1031265962 |
160 | ″ | ″ | https://doi.org/10.1186/1477-3155-12-5 |
161 | ″ | rdf:type | schema:CreativeWork |
162 | grid-institutes:grid.420020.4 | schema:alternateName | Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt |
163 | ″ | ″ | Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt |
164 | ″ | schema:name | Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt |
165 | ″ | ″ | Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt |
166 | ″ | rdf:type | schema:Organization |